穿戴式大容量注射器在皮下给药方面的应用越来越受到关注，然而尚不清楚这些新兴剂量选择是否优先于使用手持式自动注射器更频繁但剂量更小的给药方式。因此，本研究的目标是调查诊断为癌症、糖尿病、炎症和心血管疾病的患者以及能够影响治疗选择的特征和属性，以确定设备的偏好。基于一项横断面在线选择实验，191名参与者表达了他们的偏好，但未受到设备的物理暴露或执行注射。采用逻辑层次回归模型评估哪些患者特征以及治疗属性的变化驱动设备的偏好。患者生活质量降低会减少对穿戴式大容量注射器的偏好。此外，将注射频率从每两周减少至每月或每季度注射，并将注射时间从33分钟缩短到8分钟，显著增加了患者偏好大容量注射器而非自动注射器的可能性（p < 0.001）。该研究揭示了患者生活质量是设备偏好的预测因素，并确定了注射时间和注射频率的关键拐点，这些拐点使患者从手持式自动注射器转向穿戴式大容量注射器。

While interest in the use of wearable large-volume injectors for subcutaneous drug delivery is increasing, it remains unclear whether and under what conditions these emerging dosing options are preferred over more frequent but shorter administration of smaller doses using handheld autoinjectors. Therefore, the objective of this study was to examine the characteristics of patients diagnosed with cancer, diabetes, inflammatory and cardiovascular diseases, and treatment attributes that determine device preferences.Based on a cross-sectional online choice experiment, 191 participants expressed their preferences without being physically exposed to the devices or performing injections. Logistic hierarchical regression models were used to assess which patient characteristics, and how changes in treatment attributes, drive device preferences.Participant quality of life reduced the likelihood of preferring wearable large-volume injectors to handheld autoinjectors. Moreover, reducing injection frequency from biweekly to monthly to quarterly injections, and shortening injection duration from 33 to 8 min, significantly increased the likelihood of patients preferring large-volume injectors to autoinjectors (p < 0.001).The study revealed patient quality of life as predictor of device preference and identified critical inflection points in injection duration and injection frequency, at which patient preferences shift from handheld autoinjectors to wearable large-volume injectors.